GlassScriptPhysician profile
Spoorthy Challa
NPI 1457827651
$1,688.03
in general payments reported to CMS, 2019-2025
16 companies · $776 in 2025
The $776 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $35.67 · 2023: $199 · 2024: $677 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,652.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $472.65 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.59 | 2023-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $258.20 | 2023-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $182.84 | 2022-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $102.54 | 2024 | Arcalyst |
| Novo Nordisk INC | $81.53 | 2025 | Wegovy |
| Esperion Therapeutics, INC. | $77.75 | 2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $56.91 | 2022-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $44.57 | 2024-2025 | Camzyos |
| Merck Sharp & Dohme LLC | $43.35 | 2024-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $21.14 | 2025 | Farxiga |
| Regeneron Healthcare Solutions, INC. | $20.78 | 2024 | Evkeeza |
| Boston Scientific Corporation | $19.12 | 2024 | Watchman Access System |
| Amgen INC. | $16.58 | 2025 | Repatha |
| Lilly USA, LLC | $14.48 | 2025 | Zepbound |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $14.00 | 2025 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spoorthy Challa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.